EYEN•benzinga•
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Summary
Eyenovia's Phase 3 CHAPERONE study fails to meet its primary endpoint, prompting a review of strategic alternatives, including potential mergers or asset sales.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga